Carisma Therapeutics, Inc. (CARM)
NASDAQ: CARM · Real-Time Price · USD
0.2000
-0.0009 (-0.45%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Carisma Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Carisma Therapeutics stock have an average target of 0.90, with a low estimate of 0.70 and a high estimate of 1.00. The average target predicts an increase of 350.00% from the current stock price of 0.20.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Carisma Therapeutics stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 → $1 | Strong Buy | Maintains | $12 → $1 | +400.00% | Apr 1, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +5,900.00% | Jan 17, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +5,900.00% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Dec 16, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $12 | Strong Buy | Maintains | $12 | +5,900.00% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
17.24M
from 19.63M
Decreased by -12.19%
Revenue Next Year
9.28M
from 17.24M
Decreased by -46.15%
EPS This Year
-0.63
from -1.46
EPS Next Year
-0.42
from -0.63
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.0M | 19.1M | n/a | ||
| Avg | 17.2M | 9.3M | n/a | ||
| Low | 14.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.0% | 10.9% | - | ||
| Avg | -12.2% | -46.2% | - | ||
| Low | -25.1% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.30 | -0.43 | -0.61 | ||
| Avg | -0.63 | -0.42 | -0.59 | ||
| Low | -0.98 | -0.40 | -0.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.